

| <b><u>Short Name</u></b> | <b><u>Comments</u></b>  | <b><u>Type</u></b> | <b><u>Investigator</u></b>                 | <b><u>Contact</u></b>   |
|--------------------------|---|--------------------|--|---|
| A021703                  | <b>Randomized Double-blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)</b>   | Treatment          | <b>CRCWM</b><br>Physician<br>Investigators | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| WF-1806                  | <b>Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&amp;M Study</b>   | Treatment          | <b>CRCWM</b><br>Physician<br>Investigators | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| EA2182                   | <b>A Randomized Phase II Study of De-intensified Chemoradiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)</b>   | Treatment          | <b>CRCWM</b><br>Physician<br>Investigators | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| S1613                    | <b>A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER-2 Amplification</b>  | Treatment          | <b>CRCWM</b><br>Physician<br>Investigators | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| URCC 16092               | <b>A Phase II Study of Exercise and Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy</b>  | Treatment          | <b>CRCWM</b><br>Physician<br>Investigators | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| NRG GI004                | <b>Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer</b> | Treatment          | <b>CRCWM</b><br>Physician<br>Investigators | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |

|           |  |                         |  |   |
|-----------|--|-------------------------|--|---|
| S0820     | <b>A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III- Preventing Adenomas of the Colon with Eflonithine and Sulindac (PACES)</b> | Prevention              | <b>CRCWM</b><br>Physician<br>Investigators | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| A021502   | <b>ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer: A Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair</b>                                 | Treatment               | <b>CRCWM</b><br>Physician<br>Investigators | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| EAQ162CD  | <b>Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent</b>  | Cancer Care<br>Delivery | <b>CRCWM</b><br>Physician<br>Investigators | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| EA2165    | <b>A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer</b>   | Treatment               | <b>CRCWM</b><br>Physician<br>Investigators | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| FC-11     | <b>A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients with "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated</b>   | Treatment               | <b>CRCWM</b><br>Physician<br>Investigators | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| NRG GI005 | <b>Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)</b>  | Treatment               | <b>CRCWM</b><br>Physician<br>Investigators | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |

---

|                   |  |           |  |   |
|-------------------|--|-----------|--|---|
| <b>Merck-4280</b> | <b>MK-4280: A Phase I Trial of MK-4280 (LAG-3 Inhibitor) as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors (Now in Expansion Cohort, All Patients get Pembrolizumab + LAG 3 Inhibitor (MK 4280))</b> | Treatment | <b>START Midwest</b><br>Investigators      | START Midwest<br>(616) 954-5554   |
| <b>CRDF-01E</b>   | <b>An Expanded Access Program of Onvansertib in Combination with FOLFIRI and BBEVAcizumab for the Second-Line Treatment of Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC)</b>  | Treatment | <b>CHCWM</b><br>Physician<br>Investigators | CHCWM<br>(616) 954-9800<br><a href="http://www.chcwm.com">www.chcwm.com</a> |

---